Work

FIGURE 1 from Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer

Year: 2023

Type: other

Abstract: Clinical response of patients with ovarian cancer treated with p53MVA and pembrolizumab. Relative changes in tumor sizes derived from radiological evaluations (A) show that 3/28 PR patients had a decrease of 76.4%, 93.3%, and 59.5% in tumor burden (irRECIST). Twenty-one of 28 patients had at least baseline and one subsequent measurement. OS and PFS are shown in B. The numbers above the X-axis in B show numbers of patients at risk at the given timepoint after the start of treatment for OS and PFS. Two patients remain progression-free at 28 and 33 months.

DOI: 10.1158/2767-9764.24877846.v1

Authors: Ferdynand J. Kos, Paul Frankel, Mihaela Cristea, Melissa Eng, Raechelle Tinsley, Shannon Dempsey, Nora Ruel, Daphne Stewart, Thanh H. Dellinger, Don J. Diamond

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4390035119

Cites:

Cited by:

Related to: 10